DelveInsight’s ‘Community-Acquired Bacterial Pneumonia (CABP)–Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Community-Acquired Bacterial Pneumonia (CABP) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Community-Acquired Bacterial Pneumonia symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Community-Acquired Bacterial Pneumonia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Community-Acquired Bacterial Pneumonia Market Report
- As per DelveInsight's estimates, the total incident cases of Community-Acquired Bacterial Pneumonia (CABP) were 6,886,685 cases in the 7MM, which will reach 7,226,289 cases by 2032
- Among EU5 countries, Germany has the highest number of incident cases of Community-Acquired Bacterial Pneumonia (CABP), which were 568,953 cases in 2019. As per DelveInsight’s analysis, this will be 550,314 cases in 2032.
- In 2019, the incident population of Community-Acquired Bacterial Pneumonia (CABP) in the UK was found to be 414,299 cases which as per DelveInsight’s analysis, will increase to 437,410 cases by 2032.
Got queries? Click here to know more about the Community Acquired Bacterial Pneumonia Market Landscape
Community-Acquired Bacterial Pneumonia Overview
Community-acquired bacterial pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults. It is one of the most frequent respiratory illnesses among various infections triggering sepsis. The Global Burden of Disease Study identified lower respiratory tract infection (LRTI) as the second most common cause of death and years of life lost. Microbiologically, bacteria are common agents in pneumonia, with Streptococcus pneumonia being the most common cause worldwide. Streptococcus pneumonia is a bacteria most often responsible for CAP in adults worldwide. Some other common bacteria that cause CAP are Haemophilus influenza and Mycoplasma pneumonia. Pneumonia caused by chlamydia and mycoplasma is often clinically indistinguishable from other pneumonia.
Symptoms of CABP include malaise, chills, rigor, fever, cough, dyspnea, and chest pain. Cough typically is productive in older children and adults and dry in infants, young children, and older adults. Dyspnea usually is mild and exertional and is rarely present at rest. Chest pain is pleuritic and is adjacent to the infected area
Community-Acquired Bacterial Pneumonia Epidemiology Insights:
- Japan is the most aged society in the world; 25% of the Japanese population was aged ≥65 years in 2013, and an increasing number of elderly people are suffering from pneumonia; the disease is now ranked as the third cause of death in the country. Recent studies in Japan have shown that the positivity of S. pneumonia among CAP cases was 17% to 24%.
- Age and male sex are known risk factors for CAP among adults and many comorbidities are also risk factors for CAP, such as chronic obstructive pulmonary disease (COPD), diabetes, cancer, dementia, congestive heart failure, and liver function failure.
- The incidence of CAP was higher in males than in females (15.56; 95% CI, 13.90e17.43) versus 9.11 (7.87e10.55) per 10,000 inhabitants; p < 0.0001. Incidence rates increased by age (p < 0.0001) and they were higher in males than in females.
Community-Acquired Bacterial Pneumonia Epidemiology Segmentation
- Community-Acquired Bacterial Pneumonia incident cases
- Community-Acquired Bacterial Pneumonia incident cases based on gender
- Community-Acquired Bacterial Pneumonia incident cases based on the severity
- Community-Acquired Bacterial Pneumonia incident cases based on pathogen
Community-Acquired Bacterial Pneumonia Market Outlook
The Community-Acquired Bacterial Pneumonia market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Community-Acquired Bacterial Pneumonia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology. This segment gives a thorough detail of the Community-Acquired Bacterial Pneumonia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Community-Acquired Bacterial Pneumonia (CABP) market in 7MM is expected to change in the study period 2019-2032.
Learn more by requesting for sample @ Community Acquired Bacterial Pneumonia Market
Community-Acquired Bacterial Pneumonia Key Companies
- Eagle Pharma
- Takeda
- and many more
Community-Acquired Bacterial Pneumonia Therapies
- CAL02
- Cx611
- and many others
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Community-Acquired Bacterial Pneumonia
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Community-Acquired Bacterial Pneumonia Emerging Therapies
- Community-Acquired Bacterial Pneumonia Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Community-Acquired Bacterial Pneumonia Report Methodology
- DelveInsight Capabilities
- Disclaimer
Click here to read more about Community Acquired Bacterial Pneumonia Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
